Trial reportNature medicine2026
Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial.
Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Dual-Modal Wearable PPG Smartwatch with AI-Enhanced Correction for High-Accuracy and Continuous AF Burden Assessment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Incidence and clinical predictors of cognitive decline in anticoagulated patients with atrial fibrillation: the Strat-AF Study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Atrial Fibrillation and Cognitive Decline: A Systematic Review of Pathophysiological Mechanisms, Therapeutic Strategies, and Digital Health Technologies in Neuroprotection.Journal of clinical medicine · 2026Review
- Atrial fibrillation burden and oral anticoagulation: a context-dependent framework for net clinical benefit beyond binary AF definitions.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
45 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals with atrial fibrillation (AF) are at increased risk of stroke, cognitive impairment and dementia. Observational studies suggest that anticoagulation may reduce the risk of cognitive decline in patients with AF and elevated thromboembolic risk, implicating subclinical cerebral emboli as a potential mechanistic link. Whether anticoagulation prevents cognitive deterioration in patients with AF at low risk of stroke remains uncertain. Here we conducted a multicenter, double-blind, placebo-controlled trial in which participants with AF and low thromboembolic risk (CHA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.